SCHEMBL4801797

SCHEMBL4801797

Cc1nc(-c2ccc(Cl)cc2Cl)c(-c2ccc(Cl)cc2)c(S(C)(=O)=O)n1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 2/20 0.41
CNR1 P21554 8/20 0.41
HSD11B1 P28845 1/20 0.41
KDM4E B2RXH2 1/20 0.40
HPGD P15428 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
ROS1 P08922 1/20 0.39
CNR2 P34972 5/20 0.38
DPP4 P27487 2/20 0.38
ADRB3 P13945 1/20 0.38
GABRA1 P14867 1/20 0.38
ADRA2B P18089 1/20 0.38
ADRA2C P18825 1/20 0.38
HTR2A P28223 1/20 0.38
HTR2C P28335 1/20 0.38
OPRD1 P41143 1/20 0.38
SLC6A3 Q01959 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4802843 0.87 PTGS2 (0.41) PTGS2CNR1HSD11B1KDM4EHPGD
SCHEMBL4807181 0.84 CNR1 (0.40) PTGS2CNR1KDM4EHPGDNPSR1
SCHEMBL4808587 0.81 CNR1 (0.43) CNR1KDM4ECNR2
SCHEMBL4801012 0.81 CNR1 (0.47) PTGS2CNR1KDM4EHPGDNPSR1
SCHEMBL4810861 0.81 CNR1 (0.45) PTGS2CNR1CNR2
SCHEMBL4810834 0.81 PTGS2 (0.42) PTGS2CNR1HSD11B1KDM4EHPGD
SCHEMBL4807617 0.79 PTGS2 (0.38) PTGS2CNR1CNR2
SCHEMBL4809622 0.77 PTGS1 (0.42) CNR1
SCHEMBL4807071 0.76 DPP4 (0.45) PTGS2CNR1KDM4EHPGDNPSR1
SCHEMBL4809390 0.76 CNR1 (0.43) PTGS2CNR1KDM4EHPGDNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7405221-B2 Substituted pyrimidines MERCK & CO., INC. (US) 2008-07-29 US disclosed
US-7405221-B2 Substituted pyrimidines MERCK & CO., INC. (US) 2008-07-29 US disclosed
US-20050245554-A1 Substituted pyrimidines MERCK SHARP & DOHME CORP. 2005-11-03 US disclosed
EP-1546115-A2 SUBSTITUTED PYRIMIDINES Merck & Co., Inc. (US) 2005-06-29 EP disclosed
WO-2004029204-A2 SUBSTITUTED PYRIMIDINES MERCK & CO., INC. (US) 2004-04-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245554-A1 Substituted pyrimidines CNR1, CNR2, GPR119 PTGS2 1847/4885CNR1 1/4885HSD11B1 4517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.